《新股》藥捷安康公開發售超購近 3,419 倍 一手中籤僅 0.8%

TRANSTHERA-B (02617.HK) announced the results of its IPO, with the Hong Kong public offering receiving 3,419.87 times subscription, and the winning rate for one board lot (500 shares) at 0.8%. The international offering recorded 0.97 times subscription. After reallocation, the number of shares for the public offering has increased to 3.057 million shares, accounting for 20% of the total offering. The shares are expected to be listed on Monday (23rd).

The biopharmaceutical company TRANSTHERA-B is conducting a global offering of 15.281 million shares, with the public offering accounting for 10%. The offer price is HKD 13.15, raising a net amount of HKD 161 million. Five cornerstone investors, including Jiangbei Pharmaceutical, Canfite BioPharma (09926.HK), Huasheng Dunhang, Yaoshi Dihengxian, and Kelin An, collectively subscribed for HKD 130 million of the company's shares